Molecular markers of carcinogenesis in the diagnostics of cervical cancer

• Published in: Postȩpy higieny i medycyny doświadczalnej Vol. 63; p. 99
• Main Authors: Bedkowska, Grazyna Ewa, Ławicki, Sławomir, Szmitkowski, Maciej
• Format: Journal Article
• Language: Polish
• Published: Poland 27.02.2009
• Subjects: Adaptor Proteins, Signal Transducing; Antigens, Neoplasm; Biomarkers, Tumor - metabolism; Carrier Proteins; Female; Genes, bcl-2; Humans; Keratin-19; Keratins; Macrophage Colony-Stimulating Factor; Nuclear Proteins; Serpins; Tissue Polypeptide Antigen; Transcription Factor Brn-3A; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms - diagnosis; Vascular Endothelial Growth Factor A
• ISSN: 1732-2693; 1732-2693

Cervical carcinoma is the most frequent disease of the reproductive organ and is the second most common cancer in women after breast cancer. As it is characterized by high mortality, new diagnostic methods are needed, for example tumor markers, enabling earlier diagnosis and rapid detection of recurrence after therapy. Different tumor markers may be useful in the diagnostics of cervical cancer, for example squamous cell carcinoma antigen (SCC-Ag), tissue polypeptide antigen (TPA), and CYFRA 21-1, as well as some cytokines such as vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor, and macrophage colony-stimulating factor (M-CSF). About 150 genes connected with the carcinogenesis of cervical carcinoma have been identified. This paper is devoted to evaluating the diagnostic usefulness of molecular markers of carcinogenesis, especially P53, Bcl-2, Brn-3a, and MCM, and comparing the results with those of typical tumor markers or cytokines useful in diagnosing this type of cancer. It was shown that telomerase and Brn-3a proteins demonstrate usefulness in screening examination, P53 in monitoring the effectiveness of therapy, and Bcl-2 as a survival prognostic factor. In summary, it is evident that molecular makers of carcinogenesis are helpful in the diagnostics of cervical cancer, but further investigation and confirmation by a prospective study is necessary.